As one of the leading vaccine developers, GSK is keen to facilitate the exchange of intellectual know-how between the 2,000 scientists at its R&D sites in Rixensart (Belgium), Rockville (Maryland ...

Feb 15 (Reuters) - The U.S. Food and Drug Administration approved British drugmaker GSK's (GSK.L), opens new tab combination vaccine to protect against meningococcal infection for use in people ...

As a leading vaccine developer, GSK wants to combine the skills of its 2,000 scientists at R&D sites in Rixensart (Belgium), Rockville (Maryland, USA) and Siena (Italy), with the ideas and ...